Relationship between serum quantitative HBsAg and HBV DNA levels in chronic hepatitis B patients
暂无分享,去创建一个
Taicheng Zhou | Banglao Xu | Kai-hua Ming | Na Yang | Xiu-xia Lei | Zhuoran Li | Jin Feng | Zhengyu Chen | G. Liang
[1] Chuanxin Wang,et al. Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy. , 2017, Clinics and research in hepatology and gastroenterology.
[2] T. Asselah,et al. Baseline HBsAg and HBcrAg titres allow peginterferon‐based ‘precision medicine’ in HBeAg‐negative chronic hepatitis B patients , 2016, Journal of viral hepatitis.
[3] M Bertelli,et al. Prevalence of mutations in LEP, LEPR, and MC4R genes in individuals with severe obesity. , 2016, Genetics and molecular research : GMR.
[4] G. Sun,et al. Correlation between hepatitis B virus DNA levels and diagnostic tests for HBsAg, HBeAg, and PreS1-Ag in chronic hepatitis B. , 2016, Genetics and molecular research : GMR.
[5] G. Bakalos,et al. On‐treatment prediction of sustained response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B patients , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[6] T. Asselah,et al. HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[7] R. Thimme,et al. Natural history of chronic hepatitis B virus infection , 2015, Medical Microbiology and Immunology.
[8] Liang Yu,et al. Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study. , 2014, World journal of gastroenterology.
[9] Sheng-Nan Lu,et al. Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues. , 2014, World journal of gastroenterology.
[10] T. Asselah,et al. HBsAg quantification: useful for monitoring natural history and treatment outcome , 2014, Liver international : official journal of the International Association for the Study of the Liver.
[11] S. Hadziyannis,et al. Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility , 2014, Expert review of gastroenterology & hepatology.
[12] Q. Gong,et al. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B. , 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[13] T. Asselah,et al. The role of HBsAg quantification for monitoring natural history and treatment outcome , 2013, Liver international : official journal of the International Association for the Study of the Liver.
[14] T. Tseng,et al. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog , 2012, Journal of gastroenterology.
[15] K. Simon,et al. Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon &agr;-2a: progressive decrease in hepatitis B surface antigen in responders , 2012, European journal of gastroenterology & hepatology.
[16] P. Lampertico,et al. Clinical Implications of HBsAg Quantification in Patients with Chronic Hepatitis B , 2012, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.
[17] C. Peng,et al. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B , 2012, Alimentary pharmacology & therapeutics.
[18] C. Boucher,et al. A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[19] Y. Liaw. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review , 2011, Hepatology.
[20] K. Simon,et al. Early on‐treatment prediction of response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B using HBsAg and HBV DNA levels , 2010, Hepatology.
[21] S. Locarnini,et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. , 2010, Journal of hepatology.
[22] L. Demelia,et al. A randomized controlled trial of pegylated interferon-α2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B , 2009, Antiviral therapy.
[23] P. Marcellin,et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. , 2009, Gastroenterology.
[24] M. Manns,et al. A Decline in Hepatitis B virus Surface Antigen (HBsAg) Predicts Clearance, but does not Correlate with Quantitative HBeAg or HBV DNA Levels , 2008, Antiviral therapy.
[25] S. Hadziyannis. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients , 2007, Expert opinion on investigational drugs.
[26] Yoshinori Iwatani,et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. , 2004, Journal of virological methods.
[27] M. Colombo,et al. Epidemiology of hepatocellular carcinoma. , 1995, The Italian journal of gastroenterology.
[28] A. Sutnick,et al. Hepatitis and leukemia: their relation to Australia antigen. , 1968, Bulletin of the New York Academy of Medicine.